CLAIMS

1. The use of a genkwanin or sakuranetin derivative, said use being characterized in that use is made of a substance chosen from the set consisting of:

(i) saccharide derivatives of genkwanin or sakuranetin of formula I:



(I)

in which:
the symbol ——— represents a single or double bond,
R represents H or a saccharide residue, especially of structure S^1 or S^2:



(S^1)

or



(S^2)

Z represents H or a C_1-C_4 alkyl, C_1-C_5 acyl, saccharide or sulfate group, and

(ii) mixtures thereof,

as a cosmetic or dermatological active ingredient for obtaining a cosmetic or dermatological preparation for improving the texture of the skin.

2. The use of a genkwanin or sakuranetin derivative, said use being characterized in that use is made of a substance chosen from the set consisting of:

(i) saccharide derivatives of genkwanin or sakuranetin of formula I:



(I)

in which:

the symbol ——— represents a single or double bond,

R represents H or a saccharide residue, especially of structure S^1 or S^2:



(S^1) (S^2)

Z represents H or a C_1-C_4 alkyl, C_1-C_5 acyl, saccharide or sulfate group, and

(ii) mixtures thereof,

as a free-radical-scavenging active ingredient for obtaining a medicament for therapeutic use against disorders caused by free radicals.

3. The use as claimed in claim 1 or 2, characterized in that said substance is chosen from the set consisting of:

- the compounds of formula IV:



in which the symbol ⎯⎯ represents a single or double bond and Z_1 represents H or a C_1-C_4 alkyl, C_1-C_5 acyl, saccharide or sulfate group above and is advantageously a C_1-C_4 alkyl group (preferably an ethyl group) or a sulfate group (preferably an SO_3H group), and

- mixtures thereof.

4. The use as claimed in claim 1 or 2, characterized in that said substance is chosen from the set consisting of:

- 5-[O-6-(D-glucopyranosyl)-β-D-glucopyranosyl]oxy-2-(4-ethoxyphenyl)-7-methoxy-4H-1-benzopyran-4-one of formula Ia:



(Ia)

- 5-O-β-D-primeverosyl-genkwanin of formula IIa:



(IIa)

- pinostrobin-5-glucoside of formula IIIa:



(IIIa)

- 2,3-dihydro-5-[O-6-(D-gluocpyranosyl)-β-D-glucopyranosyl]oxy-2-(4-ethoxyphenyl)-7-methoxy-4H-1-benzopyran-4-one of formula Ib:



(Ib)

- 5-O-β-D-primeverosyl-sakuranetin of formula IIb:



(IIb)

- derivatives thereof in which Z is a sulfate group (preferably SO_3H or, where appropriate, SO_3Na or even SO_3NH_4), and
- mixtures thereof.

5. A saccharide derivative of genkwanin or of sakuranetin, characterized in that it is chosen from the set consisting of:

- compounds corresponding to the general formula IV:



(IV)

in which the symbol ___ represents a single or double bond and Z_1 represents H or a C_1-C_4, C_1-C_5 acyl, saccharide or sulfate group and is advantageously a C_1-C_4 alkyl group (preferably an ethyl group) or a sulfate group (preferably an

SO_3H group), and

- mixtures thereof.

6. The saccharide derivative of genkwanin as claimed in claim 5, characterized in that said derivative is a compound corresponding to formula Ia:



(Ia)

7. A process for preparing a compound of formula I as claimed in claim 1 or 2, said process being characterized in that it comprises the following steps:
(i) genkwanin, sakuranetin or a saccharide thereof is extracted from a suitable plant belonging to the set: ***Prunus, Gnidia*** and ***Daphne***;
(ii) the aglycone is osylated in position 5 with a suitable saccharide (if necessary after blocking the OH function in position 4' if it is not protected); and/or
(iii) the 4'-OH group of the saccharide extracted or prepared as indicated above (if necessary after deprotection of the 4'-OH group) is etherified (especially using an alkyl iodide so as not to affect the OH groups of the sugar portion), esterified or sulfated.

8. The process as claimed in claim 7, for preparing the compound of formula Ia as claimed in claim 4 or 6, said process being characterized in that it comprises

the steps consisting in:

(1°) extracting the ground roots of ***Daphne gnidium*** with CH_2Cl_2;

(2°) filtering to discard the methylene chloride solution thus obtained, and collecting the solid residue, which is dried;

(3°) extracting said dry solid residue thus obtained with CH_3OH;

(4°) filtering to collect the methanol solution thus obtained, and discarding the resulting solid residue;

(5°) evaporating to dryness the methanol solution thus collected, under vacuum, at a temperature of less than or equal to 60°C, to obtain a solid residue;

(6°) washing the solid residue thus obtained in step (5°), with water at a temperature of less than or equal to 60°C with stirring, and leaving to cool;

(7°) removing the washing water and then taking up the solid residue with CH_3OH;

(8°) repeating the cycle of operations of steps (5°) to (7°) 3 to 7 times until the final washing water is pale yellow and clear;

(9°) taking up the resulting dry residue in a 25/2 w/w methanol/water mixture in an amount that is suitable to obtain a liquid with a density of 0.885 g/mL;

(10°) leaving said liquid to stand at 2-4°C and preferably at 3°C, for at least 2 days and preferably for 3 days, and collecting the precipitate formed;

(11°) washing said precipitate successively with methanol and then methanol/ether mixtures with increasing ether contents, until the supernatant is colorless;

(12°) filtering off the precipitate thus obtained, and washing it several times with ether, until the washing ether is colorless;

(13°) filtering off and drying the resulting solid product, which consists of a mixture of the products of formulae Ia, IIa and IIIa; and

(14°) if necessary, separating said mixture to collect the product of formula Ia.

9. The process as claimed in claim 8, characterized in that the extraction in step (1°) is performed at a temperature of 30-35°C at atmospheric pressure or, where appropriate, at a higher temperature under reduced pressure, for 3-6 days, in apparatus of Kumagawa type; and in that the extraction in step (3°) is performed at a temperature of 45-55°C, at normal pressure or, where appropriate, at a higher temperature under reduced pressure, in the same said apparatus, for 3-6 days.

10. A cosmetic (a), dermatopharmaceutical (b) or therapeutic (c) composition, characterized in that:

(a) the cosmetic composition contains, in combination with a physiologically acceptable topical excipient, at least one compound of formula I;

(b) the dermatopharmaceutical composition contains, in combination with a physiologically acceptable and especially topical excipient, at least one compound of formula I; or

(c) the therapeutic composition contains, in combination with a physiologically acceptable and especially oral or injectable excipient, at least one compound of formula IV as immunomodulatory active ingredient,

especially against recent bouts of multiple sclerosis, or an anticancer active ingredient, especially against chronic myeloid leukemia.